Portola Pharmaceuticals to Webcast Presentation at Cowen and Company’s 39th Annual Health Care Conference
March 06 2019 - 3:10PM
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that
Scott Garland, Portola’s president and chief executive officer,
will present a corporate overview at Cowen and Company’s 39th
Annual Health Care Conference in Boston on Tuesday, March 12, 2019
at 8:40 a.m. ET (5:40 a.m. PT).
Webcast DetailsTo access the
live investor webcast on Tuesday, March 12, at 8:40 a.m. ET (5:40
a.m. PT), go to the investor section of the company’s website at
http://investors.portola.com. A replay will be available for 30
days.
About Portola Pharmaceuticals,
Inc.Portola Pharmaceuticals is a commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutics that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company’s two FDA-approved medicines are
Andexxa® [coagulation factor Xa (recombinant),
inactivated-zhzo], the first and only antidote for patients treated
with rivaroxaban or apixaban when reversal of anticoagulation is
needed due to life-threatening or uncontrolled bleeding, and
Bevyxxa® (betrixaban), the first and only oral, once-daily
Factor Xa inhibitor for the prevention of VTE in adult patients
hospitalized for an acute medical illness. The company also is
advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of
hematologic cancers.
Investor Contact: |
Media Contact: |
Cara Miller |
Pure Communications |
Portola Pharmaceuticals |
Portola_Media@purecommunications.com |
ir@portola.com |
|
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Apr 2024 to May 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles